HOW MULTIPULSE THERAPY WORKS

How MultiPulse Therapy can potentially detect and treat atrial fibrillation (AF), rapid ventricular tachycardia (VT) and ventricular fibrillation (VF).

ABOUT US

Advancing cardioversion and defibrillation using low-energy therapy

​

Cardialen, Inc. is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks.

Our MultiPulse™ Therapy (MPT) is currently being studied in an FDA-approved early feasibility IDE clinical trial exploring how a sequence of low-energy pulses timed to stop abnormal heart rhythms may restore normal heart rhythm using less energy than current high-energy shocks.

CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only 

SENIOR LEADERSHIP

Jeff Peters, President and CEO

Igor Efimov, PhD, Founder

Sumeet Dham, VP Research & Development

Tom Rasmussen, VP Clinical

Michelle Straight, Director of Quality

Kristen Swanson, Director of Regulatory

Jim McCrave, Chief Financial Officer

BOARD OF DIRECTORS

Jeff Peters, President and CEO; Director

Jay Schmelter, RiverVest Venture Partners, LLC; Director

William Schmidt, Cultivation Capital; Director

Anna French, PhD, Qiming Venture Partners; Director

Thomas Thaler, PhD, HBM Healthcare Investments; Director

Warren Watson, Independent; Director

EMPLOYMENT INQUIRIES

Interested in joining the Cardialen team?

Please complete the form.